TJ004309 + toripalimab

TJ004309 + toripalimab is an investigational combination therapy consisting of **TJ004309**, a monoclonal antibody targeting an undisclosed immunomodulatory target, and **toripalimab**, a programmed cell death protein 1 (PD-1) inhibitor monoclonal antibody[1][2]. This combination is being evaluated for advanced solid tumors, with studies aiming to assess dose, safety, pharmacokinetics, pharmacodynamics, and efficacy. Toripalimab has demonstrated efficacy as a PD-1 checkpoint inhibitor in several cancers, especially nasopharyngeal carcinoma and small cell lung cancer, and is FDA approved as Loqtorzi for these indications[3][7]. The mechanism of TJ004309 appears to be complementary immunomodulation, but its precise target is not disclosed in available studies.

Other names

Loqtorzi